Characteristics of the study participants
| . | No MGUS . | MGUS . | LC-MGUS . | ANOVA/χ2 test . |
|---|---|---|---|---|
| No. of patients | 5150 | 300 | 275 | |
| Median age (range), y | 76 (66-98) | 78 (67-93) | 79 (66-97) | P < .001 |
| Sex, no. male/female | 2104/3046 | 159/141 | 156/119 | P < .001 |
| Mean weight, kg | 75.3 | 75.4 | 76.4 | P = .50 |
| Mean height, cm | 166.7 | 167.7 | 168.0 | P = .01 |
| Current smoker (%) | 618 (12.4) | 32 (11.2) | 29 (10.9) | P = .66 |
| Osteoporosis drugs (%)* | 156 (3.0) | 6 (2.0) | 6 (2.2) | P = .44 |
| Glucocorticoids (%) | 143 (3.0) | 13 (4.7) | 10 (3.9) | P = .25 |
| . | No MGUS . | MGUS . | LC-MGUS . | ANOVA/χ2 test . |
|---|---|---|---|---|
| No. of patients | 5150 | 300 | 275 | |
| Median age (range), y | 76 (66-98) | 78 (67-93) | 79 (66-97) | P < .001 |
| Sex, no. male/female | 2104/3046 | 159/141 | 156/119 | P < .001 |
| Mean weight, kg | 75.3 | 75.4 | 76.4 | P = .50 |
| Mean height, cm | 166.7 | 167.7 | 168.0 | P = .01 |
| Current smoker (%) | 618 (12.4) | 32 (11.2) | 29 (10.9) | P = .66 |
| Osteoporosis drugs (%)* | 156 (3.0) | 6 (2.0) | 6 (2.2) | P = .44 |
| Glucocorticoids (%) | 143 (3.0) | 13 (4.7) | 10 (3.9) | P = .25 |
P values shown in bold represent P < .05.
Bisphosphonates, calcitonin, and lasofoxifene.